成人复发/难治性急性髓系白血病的治疗
本文综述成人复发/难治性急性髓系白血病的治疗现状:异基因造血干细胞移植仍是缓解后最有效手段,但移植相关死亡与复发率高,许多患者不适合移植;随着对发病机制和免疫抗白血病作用的认识加深,多种小分子抑制剂和免疫治疗正在临床试验及临床前阶段探索。
要点
- 复发后达完全缓解者,异基因造血干细胞移植仍是最有效治疗手段。
- 移植相关死亡率和复发率均高,许多患者不适合移植。
- 小分子抑制剂和免疫治疗正在临床试验及临床前阶段探索。
核心结论
- 复发/难治性急性髓系白血病预后差、治疗困难,目前不经异基因造血干细胞移植治愈可能性低,但治疗毒性在降低、缓解持续时间在延长。
研究设计与样本
- 综述,围绕成人复发/难治性急性髓系白血病的治疗进行总结。
主要发现
- 复发后达完全缓解者,异基因造血干细胞移植仍是最有效的治疗手段。
- 异基因造血干细胞移植的移植相关死亡率和复发率均高,许多患者不适合该治疗。
- 多种小分子抑制剂和免疫治疗正在临床试验中探索,更多处于临床前阶段。
临床怎么用
- 未来研究将聚焦于新型且机制驱动的联合方案、序贯治疗和低毒性维持策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is challenging. While the most potent treatment modality for patients who achieve a complete remission after relapse is still allogeneic haematopoietic cell transplantation (allo-HCT), both transplant-related mortality and relapse rates are high and many patients are not candidates for this approach. After a few decades of relative stasis in this field, a large number of novel approaches have become available to tackle this highly fatal disease. This is mostly due to our improved understanding of disease pathogenesis (including targetable mutations) and the anti-leukaemia potential of the immune system. Several small-molecule inhibitors and immunotherapeutic options are being explored in clinical trials and many more are in pre-clinical phase. Future studies will focus on novel and mechanistically driven combinations, sequential treatments, and low-toxicity maintenance strategies. While cure of relapsed/refractory AML without allo-HCT is currently unlikely, treatments are becoming less toxic and remissions are lasting longer.
引用
- Rashidi A, Weisdorf DJ, Bejanyan N, et al. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol. 2018. PMID: 29318584. doi:10.1111/bjh.15077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。